Expression of CD40L on CD4+T cells distinguishes active versus inactive HIV-associated Kaposi's Sarcoma
- PMID: 33799006
- PMCID: PMC8127409
- DOI: 10.1016/j.ctarc.2021.100361
Expression of CD40L on CD4+T cells distinguishes active versus inactive HIV-associated Kaposi's Sarcoma
Abstract
Kaposi's sarcoma (KS) is a malignancy of vascular origin. It is caused by the Kaposi's sarcoma-associated herpes virus (KSHV). Immune dysregulation is a key feature in the development and progression of KS. The main aim of this study was to determine and compare circulating CD4+ and CD8+T cell subsets including their expression of CD40 ligand (CD40L) and programmed cell death protein 1 (PD1), natural killer (NK) cells, and NK T cells between individuals with active HIV-associated KS versus those in remission. We found that the proportion of CD4+T cells was significantly higher in individuals in remission compared to those with active KS (26.3% vs 13.9%; p = 0.01). We also observed that the proportion of CD4+T cells and central memory CD4+T cells expressing CD40L was significantly higher in individuals with active KS versus those in remission, (10.6% vs 5.4%; p = 0.03) and (14.8% vs 5.9%; p = 0.01) respectively. There was no significant difference in proportion of CD4+ and CD8+ naïve, central memory, effector memory, and terminal effector cells between the two groups. In addition, there was no difference in expression of PD1 on the T cell subsets between the two groups. Furthermore, the proportion of NK cells and NK T cells were not differential between individuals with active disease versus those in remission. CD40L expression is higher in individuals with active HIV-associated KS compared to those in remission. The proportion of CD4+T cells is higher in individuals in remission compared to those with active HIV-associated KS.
Keywords: CD40L; HIV; Kaposi's sarcoma; Natural killer cells; PD1; T cell subsets.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest
The authors have no conflicts of interest to disclose.
Figures

Similar articles
-
Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels.AIDS Res Hum Retroviruses. 1999 Jan 1;15(1):51-5. doi: 10.1089/088922299311709. AIDS Res Hum Retroviruses. 1999. PMID: 10024052
-
Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count.J Med Virol. 2007 Oct;79(10):1562-8. doi: 10.1002/jmv.20949. J Med Virol. 2007. PMID: 17705173
-
Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.AIDS. 2007 Jun 19;21(10):1245-52. doi: 10.1097/QAD.0b013e328182df03. AIDS. 2007. PMID: 17545700 Clinical Trial.
-
Kaposi's sarcoma in HIV infected women in Germany: more evidence for sexual transmission. A report of 10 cases and review of the literature.Genitourin Med. 1994 Dec;70(6):394-8. doi: 10.1136/sti.70.6.394. Genitourin Med. 1994. PMID: 7705856 Free PMC article. Review.
-
Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS.Infect Agents Dis. 1996 Oct;5(4):215-22. Infect Agents Dis. 1996. PMID: 8884366 Review.
Cited by
-
CD8+ T cell clonotypes from prior SARS-CoV-2 infection predominate during the cellular immune response to mRNA vaccination.Res Sq [Preprint]. 2022 Oct 10:rs.3.rs-2146712. doi: 10.21203/rs.3.rs-2146712/v1. Res Sq. 2022. PMID: 36263073 Free PMC article. Preprint.
-
SARS-CoV-2-Specific T Cell Immunity in HIV-Associated Kaposi Sarcoma Patients in Zambia.J Immunol Res. 2022 Jul 28;2022:2114285. doi: 10.1155/2022/2114285. eCollection 2022. J Immunol Res. 2022. PMID: 35935575 Free PMC article.
-
Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19.Nat Immunol. 2024 Jan;25(1):166-177. doi: 10.1038/s41590-023-01692-x. Epub 2023 Dec 6. Nat Immunol. 2024. PMID: 38057617 Free PMC article.
References
-
- Innis-Whitehouse W, Wang X, Restrepo N, Salas C, Moreno K, Restrepo A, et al. Kaposi sarcoma incidence in females is nearly four-fold higher in the Lower Rio Grande Valley compared to the Texas average. Cancer Treat Res Commun. 2018;16:45–52. - PubMed
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials